1106 results for Support
Refine Your Search
Keith
Hi! My name is Keith. I’m currently 37 years old. I was diagnosed on November 6, 2015, with diffuse large B-cell lymphoma (DLBCL). My wife, Tesia, was…
Rebecca
Less than one month before finishing her clinical fellowship year as a speech-language pathologist, Becca was diagnosed with Hodgkin’s lymphoma. Her l…
Teresa
I was diagnosed in 2009 with chronic lymphocytic leukemia (CLL). Upon diagnosis, perhaps the greatest shock was becoming aware that I knew so little a…
Suggested Reading - Shelter from the Storm: Caring for a Child with a Life-Threatening Condition
Shelter from the Storm: Caring for a Child with a Life-Threatening Condition By Joanne Hilden, M.D., and Daniel R. Tobin, M.D. Perseus Publishing, 20…
A phase 2 study of Bexmarilimab, an anti-Clever1 monoclonal antibody, in combination with azacitidine in patients with high-risk MDS
In June 2022, LLS made an equity investment in Faron Pharmaceuticals to "Support Clinical Development of the Bexmarilimab Program for Leukemia Indicat…
Centers for Disease Control and Prevention (CDC)
Collaborating to create the expertise, information, and tools that people and communities need to protect their health – through health promotion, pre…
A phase 1 study of KT-413, a dual degrader of IRAK4 and IMiD substrates, in patients with DLBCL
In March 2020, LLS made an equity investment in Kymera Therapeutics to "Support Key Studies with IRAK4 Protein Degraders for Future Development in Hem…
A phase 1/2 study of Bexmarilimab, an anti-Clever1 monoclonal antibody, in combination with azacitidine or azacitidine/venetoclax in patients with AML, MDS or CMML
In June 2022, LLS made an equity investment in Faron Pharmaceuticals to "Support Clinical Development of the Bexmarilimab Program for Leukemia Indicat…
Katie
In October 2021, I was diagnosed with stage 2 Hodgkin lymphoma (HL). This journey of over 100 appointments has not been easy and something I never wou…
The Immune Niche in the Development of Hematological Malignancies and Implications for Novel Therapy
Our SCOR Program, composed of four complementary Projects supported by three shared Cores, is designed to determine how the immune niche and factors i…
Stories of Hope, Adaptation, Resilience, and Empowerment (SHARE)
This series of engaging and impactful episodes feature key opinion leaders and blood cancer survivors who discuss a wide range of topics, including tr…
“Stages” of Leukemia: Understanding Classification and Progression
Table of contentsStages of Leukemia Chronic Lymphocytic Leukemia (CLL) Acute Lymphoblastic Leukemia (ALL) Acute Myeloid Leukemia (AML) Chronic Mye…
Nikki
If you were to sit down with Nikki Henshaw, you'd find out she has a full and blessed life. She has a supportive husband, two beautiful children, and …
Ask the Expert: Acute Myeloid Leukemia (AML)
Video coming soon. Topics CoveredPatients and care partners will have an opportunity to connect directly with an acute myeloid leukemia (AML) speciali…
Tracey
I was diagnosed with chronic lymphocytic leukemia (CLL) in 2021 after a routine physical after my 50th birthday. It was a complete shock and I was sca…
Sophia
When I was in middle school, my dad was diagnosed with acute lymphoblastic leukemia (ALL). During this time, The Leukemia and Lymphoma Society deeply …
A phase 1 study of AUTX-703, a KAT2A/B degrader, in patients with AML or MDS
In June 2025, LLS made an equity investment in Auron Therapeutics to "Support Clinical Development of AUTX-703 in Relapsed/Refractory AML and MDS."Aur…
Research: TAP
Pan-heme CAR: Anti-CD38 CAR T cells for myeloid, lymphoid and plasma cell malignancies
Our SCOR team has a razor-sharp focus on an exciting new treatment modality for blood cancers: chimeric antigen receptor (CAR) T cells. T cells can be…
A phase 1 study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies
In August 2018, LLS partnered with Sutro Biopharma to support "A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-00…
A phase 1/2 study of IMT-009, an antibody targeting CD161, in patients with advanced solid tumors or lymphomas
In August 2021, LLS made an equity investment in Immunitas Therapeutics to support the "Phase 1 Clinical Development of IMT-009, an Antibody Targeting…
A phase 1 study of KT-333, a STAT3 protein degrader, in patients with NHL
In March 2020, LLS made an equity investment in Kymera Therapeutics to "Support Key Studies with STAT3 Protein Degraders for Future Development in Hem…
Stupid Cancer
To empower, support, and improve health outcomes for the young adult cancer community Offers CancerCon - an annual 4-day gathering which include…
Contact us
Whether you’re looking to get in touch for patient support, fundraising, ways to donate, how to volunteer, or another topic relating to blood cancers,…
About Us
Suzanne
In January 2021, I received my diagnosis after five months of multiple doctor visits, blood work, and biopsies. I had no common symptoms, such as nigh…
Shirley
The Boston Marathon marked my 33rd fundraiser for The Leukemia & Lymphoma Society (LLS), the 27th race with Team In Training (TNT), and the 6th Abbott…